首页> 中文期刊> 《中华医学杂志(英文版)》 >Progression of solitary and multifocal papillary thyroid carcinoma— a retrospective study of 368 patients

Progression of solitary and multifocal papillary thyroid carcinoma— a retrospective study of 368 patients

         

摘要

Background Papillary thyroid carcinoma (PTC) represents one of the most frequent endocrine malignancies.Several factors have been found to be involved in determining the outcome of treatment for patients with PTC.Large tumor size,diagnosis at an early age,extra-thyroidal invasion,aggressive histological variants,and distant metastases are the most important determinants of a poor outcome.BRAFv600E mutation has been found to be a major genetic alteration in PTC.This study aimed to evaluate progression in patients with multifocal and solitary PTC.Methods We performed a retrospective study to analyze 368 patients with PTC who underwent surgery,including 282 patients with solitary PTC and 86 patients with multifocal PTC.The status of BRAFv600E mutation in all tumor foci from multifocal PTC was detected.Results Our study suggested that multifocal PTC was more related to lymph node metastasis and vascular invasion than solitary PTC.However,the distant metastasis rate and 10-year survival rate showed no difference between these two groups.The number of tumor foci did not affect progression of disease in multifocal PTC patients.Lymph node metastasis in multifocal PTC patients was associated with larger tumors,diagnosis at early stage,and extra-thyroidal invasion.Conclusion The status of BRAFv600E mutation was more frequent in multifocal PTC patients with lymph node metastasis and diagnosis at later age.

著录项

  • 来源
    《中华医学杂志(英文版)》 |2012年第24期|4434-4439|共6页
  • 作者单位

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Othopaedics, General Hospital of Chinese People's Liberation Army, Beijing 100853, China;

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital,Oncology Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号